Advertisement

Topics

Latest "New England Biolabs, Inc." News Stories

17:21 EDT 20th October 2018 | BioPortfolio

Here are the most relevant search results for "New England Biolabs, Inc." found in our extensive news archives from over 250 global news sources.

More Information about New England Biolabs, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about New England Biolabs, Inc. for you to read. Along with our medical data and news we also list New England Biolabs, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of New England Biolabs, Inc. Companies for you to search.

Showing "England Biolabs" News Articles 1–25 of 1,600+

Saturday 20th October 2018

Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer

Results Presented at the ESMO 2018 Congress (European Society for Medical Oncology) and Simultaneously Published in The New England Journal of Medicine Pfizer Inc.(NYSE:PFE) today announced detail...


Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE® (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer

Results Presented at the ESMO 2018 Congress (European Society for Medical Oncology) and Simultaneously Published in The New England Journal of Medicine Pfizer Inc.(NYSE:PFE) today announced detailed overall survival (OS) data from the PALOMA-3 trial, which evaluated IBRANCE® (palbociclib) in combination with fulvestrant compared to placebo p...

Genentech’s Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer

– Tecentriq combination first immunotherapy regimen to demonstrate positive Phase III results in breast cancer – – Tecentriq and nab-paclitaxel significantly reduced the risk of disease worsening or death in both the intention-to-treat and PD-L1-positive populations – – Clinically meaningful overall survival improvement in the ...


Genentech’s Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment ...

– Data are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress, featured in the press program and simultaneously published in the New England Journal of Medicine on October 20, 2018 – Read more...

ASPIRINE : Peut-elle à faible dose permettre de prolonger la vie ?

On pourrait en effet penser qu’une faible dose quotidienne d’aspirine, chez les personnes âgées, est favorable à la santé cérébrovasculaire et peut avoir un effet positif sur la durée de vie en bonne santé. 3 articles publiés dans le New England Journal of Medicine nous livrent les premiers résultats de la cohorte ASPREE (ASPirin in […]

News digest – ‘No-deal’ Brexit predictions, nurse shortages and a ‘surprising’ DNA discovery

Science blog Drug approvals could be delayed by a ‘no-deal’ Brexit Access to treatments being reviewed in Europe, including cancer drugs, could be delayed if the UK and EU can’t agree terms on Brexit, reports the Independent. Drug manufacturers have been told they would need to apply for UK approval separately unless a deal is agreed on drug regulation. For the latest on how a ‘no-...

Friday 19th October 2018

Mylan Launches Hulio (Biosimilar Adalimumab) in Markets Across Europe

HERTFORDSHIRE, England and PITTSBURGH, Oct. 19, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it has initiated the commercial launch of Hulio, a ...

GP trainees recruited in England surpass target

The number of doctors entering GP training in England this year has surpassed the target set by Health Education England (HEE) by more than 200.HEE said that 3473 trainees were starting their GP...

NEJM retracts article from former researcher once hailed as heart stem cell pioneer

The New England Journal of Medicine has retracted one paper1 and issued an “expression of concern” about two others2 within days of Harvard Medical School and Brigham and Women’s Hospital announcing...

Brexit: hospitals told to identify contracts that could be affected by “no deal”

The UK government has told NHS hospitals in England to draw up a list of all contracts that could be affected in the event of the UK failing to negotiate a deal to exit from the European Union.In a...

MtoZ Biolabs Released a Series of Glycoprotein Analysis Services

Glycosylation, as a a post-translational modification, has the feature of structural complexity, which increases the difficulty of analysiing glycoproteins. Although it has been predicted that about 50 percent proteins are glycosylated, only 10 percent glycoproteins have been identified so far. To support researchers in glycoprotein related study, MtoZ Biolabs provides LC-MS/MS based glycosylation...

Thursday 18th October 2018

Journal Retracts Stem Cell Work by Former Harvard Scientist

NewsThe New England Journal of Medicine has retracted a 2011 study and is investigating two earlier ones describing stem cell research by a former Harvard Medical School scientist, Dr. Piero Anversa.

Your NEJM Group Today: Aspirin for Primary Prevention? / Bariatric Surgery, Diabetes & CV Outcomes / Kentucky Hospitalist Opportunities

Here's what we chose for you from NEJM Group today: New England Journal of Medicine: Editorial: Dr. Paul Ridker asks, should aspirin be used for...

Tufts Medical Center Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12102018] Prices from USD $250

SummaryTufts Medical Center TMC, formerly New England Medical Center Hospital Inc, a subsidiary of Tufts University School of Medicine, is an academic medical center that provides patient care services. The center offers treatments for brain tumor, breast cancer, cardiac arrhythmia, cardiomyopathy, celiac disease, cervical cancer, epilepsy, heart disease, in vitrofertilization, urinary incontinenc...

Obesity in Year 6 pupils at record high

News report Levels of obesity among 10-11-year olds has hit record high, according to Public Health England.  The study showed that in 2016/17 there were 190,574 Year 6 pupils who were either overweight or obese. In 2017/18 an extra 7,314 children in Year 6 fell into this category.  According to PHE, around 5 in 100 children aged 10-11 years old are now in the highest weight category.  The d...

Vertex Data Presented at North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding and Enhancing Options for Treating the Underlying Cause of Cystic Fibrosis

- Phase 2 results of VX-659 and VX-445 triple combination regimens concurrently published in The New England Journal of Medicine - - Phase 3 ARRIVAL data support treating the underlying cause of cystic fibrosis with KALYDECO® (ivacaftor) as early as six months of age - - Patient-reported outcomes data from Phase 3 EVOLVE and EXPAND ...

Amgen Invests $66 Million in Oxford Nanopore Technologies

THOUSAND OAKS, Calif. and OXFORD, England, Oct. 18, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Oxford Nanopore Technologies Ltd. today announced Amgen’s equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. Oxford Nanopore has developed and brou...

Telix Pharmaceuticals Limited (TLX-AU): Novartis Endocyte move highlights opportunity

goetzpartners securities Limited 18-Oct-2018 / 12:51 GMT/BST Free to access research and investor meetings in a post-MiFID2 world. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clien...

-GSK cuts 190 jobs in #Ulverston -NHS England approves Gilead's #Yescarta -#Trump signs trust-busting #biosimilar bill -FDA approves #HPVvaccine for 27-45 year olds Check out last week's Top Ten most popular articles http://bit.ly/2pQtfbR  #pharma

-GSK cuts 190 jobs in #Ulverston -NHS England approves Gilead's #Yescarta - #Trump signs trust-busting #biosimilar bill -FDA approves #HPVvaccine for 27-45 year olds Ch

Amgen Invests £50 Million ($66 Million) In Oxford Nanopore Technologies

THOUSAND OAKS, Calif. and OXFORD, England, Oct. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Oxford Nanopore Technologies Ltd. today announced Amgen's equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. Oxford Nanopore has developed and brought to market a prop...

Clinipace's Growth Supported by New Executive Leadership and Investment in Clinical Technology

Clinipace, a global full-service contract research organization (CRO), has named industry executive John Cargill as its chief commercial officer and announ

Small children prioritised under emergency protocol to tackle 'critical' EpiPen shortage

Supplies of adrenaline auto-injectors for children are now “critical” and are being rationed with new national guidance for community pharmacists being introduced across England.

MedMen Real Estate Assets Seed New Investment Vehicle

Transaction Unlocks Capital as Company Continues to Grow its Footprint MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQB: MMNFF) (FSE: A2JM6N) today announced that it has reached agreement to sell a significant portion of its real estate assets to the newly formed Treehouse Real Estate Investment Trust (“Treehouse...

Vision care for low-income communities in the Dominican Republic

Gildan and Batey Relief Alliance bring ophthalmologists to communities in need of eye care SOURCE: Gildan Activewear DESCRIPTION:Gildan, in partnership with the Batey Relief Alliance (BRA), organized its second “Blindness Prevention” program for the community of San Pedro de Macoris, San Antonio de Guerra and other areas of eastern Dominican Republic.  The event took place over four consecut...

Wednesday 17th October 2018

Concerns about the promotion of a cardboard baby box as a place for infants to sleep

The successful reduction in cot deaths (sudden infant death syndrome or SIDS) in England and Wales from nearly 1600 deaths in 1988 to less than 200 in 2015 stems from evidence based research.1...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks